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Acute kidney injury is a devastating syndrome that aﬄicts over 2,000,000 people in the US per year, with an associated mortality
of greater than 70% in severe cases. Unfortunately, standard-of-care treatments are not suﬃcient for modifying the course of
disease. Many groups have explored the use of bone marrow stromal cells (BMSCs) for the treatment of AKI because BMSCs
have been shown to possess unique anti-inﬂammatory, cytoprotective, and regenerative properties in vitro and in vivo.I ti sy e t
unresolved whether the primary mechanisms controlling BMSC therapy in AKI depend on direct cell infusion, or whether BMSC-
secreted factors alone are suﬃcient for mitigating the injury. Here we show that BMSC-secreted factors are capable of providing
a survival beneﬁt to rats subjected to cisplatin-induced AKI. We observed that when BMSC-conditioned medium (BMSC-CM) is
administered intravenously, it prevents tubular apoptosis and necrosis and ameliorates AKI. In addition, we observed that BMSC-
CM causes IL-10 upregulation in treated animals, which is important to animal survival and protection of the kidney. In all,
these results demonstrate that BMSC-secreted factors are capable of providing support without cell transplantation, and the IL-10
increase seen in BMSC-CM-treated animals correlates with attenuation of severe AKI.
1.Introduction
Each year approximately 2,000,000 people in the US develop
acute kidney injury (AKI), with a likelihood of death greater
than 70% in cases of dialysis dependence [1, 2]. AKI is
an inﬂammatory organ failure syndrome that is caused
by extensive injury to the kidney parenchyma [3]. There
are various etiologies of AKI that stem from prerenal,
intrinsic renal, or postrenal causes. Regardless of etiology,
however, it is thought that there is persistent systemic
inﬂammation that may contribute to prevention of tissue
regeneration and disease reversal [4]. Resolution may be
achievable if the inﬂammatory cytokine storm created by
AKI can be attenuated, and support is provided to aid in
the healing of the injured tissue [5]. Unfortunately, the
only existing therapies available to patients with AKI are
palliative. Dialysis, while useful to restore electrolyte balance
andremovewasteproductsintheblood,weaklysupplements
the failing kidneys without providing anti-inﬂammatory or
regenerative support [6]. Single molecule therapies directed
against AKI have thus far proven insuﬃcient for addressing
the complex pathophysiology underlying the disease [7].
New therapies that can resolve the disease by addressing
multiple aspects of AKI pathophysiology in parallel are
desperately needed.
Bone marrow stromal cells (BMSCs) have been explored
in preclinical and clinical studies as a potential therapeutic
forpatientswithAKI[8].BMSCshavebeenshowntopossess
potent immunomodulatory and regenerative properties in
vitro and in vivo [9, 10]. The predominant mechanisms of2 Stem Cells International
BMSC therapy are unclear. Some studies implicate homing,
engraftment and diﬀerentiation as critical for therapeutic
beneﬁt [11], and others stress the importance of secreted
factors from BMSCs as the key mediators [12]. To attempt to
resolve this issue, we and others have tested BMSC-secreted
factors in various disease models and compared them to
whole cell transplantation. These studies have demonstrated
that BMSC-secreted factors possess the capacity to provide
therapeutic support to rodents suﬀering from acute diseases
associated with inﬂammation (e.g., liver failure, sepsis),
and can provide superior support when compared to cell
transplantation [13–15]. In particular, we have seen that
BMSC-secreted factors are responsible for a reversal of
proinﬂammatory cytokine expression and a concomitant
increase in the anti-inﬂammatory cytokine interleukin-10
(IL-10). To date, it has not yet been deﬁnitively resolved
whether this is also the case in AKI. It has been shown
in several models of AKI that these factors are capable
of providing signiﬁcant support [16–18], as measured
by a reduction in the total injury to the renal tubule
epithelium, and preservation of glomerular ﬁltration rate
and creatinine clearance in ischemic and rhabdomyolytic
injury models. T¨ ogel and colleagues [16]a n dD u ﬃeld et al.
[19] demonstrated that when BMSCs are infused in the
context of AKI, very few cells engraft within hours of
transplantation, and few cells can be detected in the kidneys
after 24 hours which is consistent with other studies that
also suggest the half life of BMSCs in vivo is on the order of
days [20, 21]. Nevertheless, they still observed improvement
of the structure and function of kidneys during ischemic
AKI. In addition, they observed a similar reduction of the
proinﬂammatory injurious state during AKI as we have seen
in other inﬂammatory disease models with BMSC-secreted
factors, as evidenced by suppression of proinﬂammatory
cytokine expression and upregulation of the expression of
anti-inﬂammatory mediators in the kidney at the level of
mRNA, including IL-10.
In the current paper, we demonstrate that BMSC-
secreted factors are capable of protecting rats from devel-
oping severe AKI after cisplatin treatment and can provide
a survival beneﬁt without cell transplantation. Compared
to vehicle and a mock cell control, we saw a statistically
signiﬁcant survival beneﬁt conferred by BMSC conditioned
medium(CM),togetherwithareducitonofbothhistological
and serum kidney function parameters. In addition, we
observed a signiﬁcant increase in serum IL-10 levels in
animals treated with BMSC-CM, and when IL-10 was
neutralized using an antibody, the eﬀects of the BMSC-CM
were signiﬁcantly abated. The results of this study clearly
indicate that in AKI, the secreted factors alone are suﬃcient
for reduction of injury and prolonged survival.
2. Methods
2.1. Cell Culture and Conditioned Medium. BMSCs were
isolated, puriﬁed, grown, and characterized, and ﬁbroblasts
grown as described previously [22, 23]. Brieﬂy, BMSCs
were isolated from whole bone marrow (Lonza, Basel,
Switzerland) by selective adhesion and expanded in colonies
for seven days. Colonies were trypsinized and replated for
further expansion. Purity of culture (>99%) was determined
with ﬂow cytometry (results not shown) by staining BMSCs
with BD Pharmingen CD44, CD45, CD29, CD73, CD106, or
CD11b antibodies (BD, Franklin Lakes, NJ). All BMSCs were
used at passage 2–5. Fibroblasts were cultured from the cell
line PCS-201-012 (ATCC, Manassas, VA). The conditioned
medium was collected and concentrated as described previ-
ously [24]. Brieﬂy, both cell types (BMSCs and ﬁbroblasts)
were grown to 60% conﬂuence, rinsed with PBS twice, and
then incubated for 24 hours in the presence of serum-free
DMEM containing 0.05% bovine serum albumin (Sigma,
St. Louis, MO). The conditioned medium was collected
and concentrated using Amicon centrifugal concentrators
with a 3kDa cutoﬀ (Millipore, Billerica, MA). Other than
culturing in the presence of diﬀerent cells, conditioned
media from BMSCs and ﬁbroblasts (FBs) were collected
and prepared identically. By convention, “1X” refers to the
concentration of conditioned medium achieved when 15mL
of conditioning medium was incubated in the presence of
2 × 106 cells for 24 hours, collected, and concentrated to a
ﬁnal volume of 1mL. This preparation was used for both
BMSCs and ﬁbroblasts for the purposes of these studies.
2.2. Rat Model of Cisplatin-Induced Acute Kidney Injury
and BMSC-CM Treatment. All animal studies were per-
formed in accordance with the animal rights policies of the
Massachusetts General Hospital Subcommittee on Research
Animal Care. Male SAS-SD rats (Charles River Laboratories,
Wilmington, MA) weighing 275–300g were given cisplatin
(7.5mg/kg; Sigma, St. Louis, MO) dissolved in physiological
saline via i.p. injection to induce AKI. At various time
points after injection, BMSC-CM, FB-CM, physiological
saline, or mixtures of BMSC-CM plus anti-rat IL-10Ab
(BD, Franklin Lakes, NJ; Invitrogen, Carlsbad, CA) were
administered intravenously via penile vein as treatments for
the cisplatin-induced AKI. All BMSC-CM and FB-CM doses
consisted of 1mL of 1X CM per dose, and in all cases, the
concentration of IL-10Ab in each dose was 4μg diluted in
1mL of conditioned medium.
2.3. Tissue Histology and Staining. Rats were anesthetized
with isoﬂuorane (Hospira, Lake Forest, IL), and laparotomy
was performed to access the abdominal cavity. Euthana-
sia was performed by severing the abdominal aorta and
puncturing the diaphragm. Both kidneys were excised and
rinsed with physiological saline before ﬁxation in buﬀered
formaldehyde (Sigma, St. Louis, MO) for one week at room
temperature. The kidneys were then embedded in paraﬃn
wax and 4μm sections were created using a microtome.
The sections were then analyzed by either (1) staining with
hematoxylin and eosin (H&E), (2) TUNEL according to
themanufacturer’sinstructions(R&DSystems,Minneapolis,
MN), (3) probed with PCNA antibody as described previ-
ously[25],or(4)stainedforkidneyinjurymolecule-1(KIM-
1) [26]. All tissues were collected from euthanized animals 5
days following i.p. injection of cisplatin. For the H&E sec-
tions, histological scoring was performed on rats subjectedStem Cells International 3
to AKI and treated with either saline, BMSC-CM or BMSC-
CM + anti-rat IL-10 antibodies, three rats per group,
respectively. Three microscopic ﬁelds at 40X magniﬁcation
on a Nikon Optiphot-2 were analyzed per animal for each
of three regions of the kidneys, outer cortex (OC), inner
cortex (IC), and outer stripe of the outer medulla (OSOM).
Tubular injury was quantiﬁed based on observed dilation,
loss of brush border, cast, debris, thinning, and cell loss. The
quantitative score was based on the following metric: 0 =
normal; 1 = 1–25% injury; 2 = 26–50% injury; 3 = 51–
75% injury; 4 = 76–100% injury. Apoptosis was quantiﬁed
by taking the average number of TUNEL positive cells in
four ﬁelds at 10X of the medulla and cortex of rats subjected
to cisplatin AKI and treated with either saline (n = 4) or
BMSC-CM (n = 3). For the PCNA staining, we used an
anti-PCNA clone PC10 (Sigma, St. Louis, MO), followed by
a secondary sheep anti-mouse (1:50; Chemicon, Temecula,
CA), and signal development using the Vectastain ABC kit
(Vector Labs, Burlingame, CA). To determine the number
of PCNA positive cells per ﬁeld, representative images were
taken at 20X magniﬁcation of the kidney samples for each
of three animals, 5 images of the medulla and 5 images of
the cortex, and the numbers of positive cells per ﬁeld were
counted and tabulated. Kidney injury molecule-1 KIM-1
was stained as described previously [26, 27]. Brieﬂy, 4μm
paraﬃn sections were rehydrated and KIM-1 was labeled
witha goatanti-rat Tim-1/KIM-1 polyclonal antibody (R&D
Systems, Minneapolis, MN). The secondary antibody used
was donkey anti-goat Biotin-SP-conjugated, and the signal
was developed using ABC peroxidase DAB labeling. The
sections were then counterstained with hematoxylin. For
TUNEL, PCNA, and KIM-1 staining, isotype controls were
performed, in addition to a healthy kidney control for
comparison (results not shown).
2.4.BloodUreaNitrogen(BUN)andCreatinineMeasurement.
All BUN and creatinine measurements were conducted
with blood drawn from the rats and analyzed on a Renal
Function Panel according to manufacturer’s instructions
(Abaxis, Union City, CA). For BUN and creatinine analysis,
all animals were sacriﬁced ﬁve days after i.p. injection of
cisplatin and induction of AKI.
2.4.1. IL-10 ELISA. The rat IL-10 ELISA kit used was
provided by a commercial vendor and was used according
to the manufacturer’s instructions (OptEIA ELISA kit; BD,
Franklin Lakes, NJ). Blood was drawn from animals via tail
sniponday3andserawereanalyzedforthepresenceofIL-10
using this commercial kit. BMSC-CM was also analyzed for
IL-10 using the same kit to assess whether the measured IL-
10intheseraoftheanimalswasattributedtotheBMSC-CM.
2.4.2. Statistics. Unless otherwise noted, all experiments
were repeated in quadruplicate, and all data were assessed
for signiﬁcance using a paired, two-tail Student’s t-test. All
graphs display the average value of each experimental group
with error bars indicating one standard deviation in the
spread of the data.
3. Results
3.1. BMSC-CM Attenuates Cisplatin-Induced AKI in Rat.
In these studies, we chose to use a cisplatin model of
AKI in rats. Cisplatin is used routinely in the clinic as a
cancer chemotherapeutic agent and remains the standard of
care for many malignancies, including ovarian and cervical
cancer, because of its strong therapeutic track record [28,
29]. However, one of the most common and dangerous
complications of cisplatin administration is nephrotoxicity
[30] ,w h i c hc a nl e a dt od e a t hw i t hA K I .T h ep r i m a r y
hypothesis tested was whether BMSC-secreted factors, when
used to treat lethal cisplatin administration, could provide
the multifactorial support required to protect the kidneys
and prevent death by organ failure.
We began our studies by optimizing the cisplatin dose
required to induce 75% mortality by two weeks and arrived
upon 7.5mg/kg i.p. [31] .W et h e nd e t e r m i n e da ne ﬀective
regimen for treating AKI with BMSC-CM. Previous stud-
ies illustrating the kinetics of disease onset demonstrated
irreversible damage within the ﬁrst 72 hours after cisplatin
administration [32]. Hence, we chose ﬁve time points for
repeated i.v. administration of BMSC-CM: 3, 9, 24, 48, and
72 hours after cisplatin was given. This regimen provided a
signiﬁcant survival beneﬁt (Figure 1); compared to controls
(FB-CM, n = 10; saline, n = 12), BMSC-CM (n = 14)
improved survival from 25% to 71.4% (P<0.05) [22].
In addition to providing a survival beneﬁt, BMSC-CM also
signiﬁcantly attenuated the severity of cisplatin AKI. When
animals were administered the same dose of cisplatin, BUN
andcreatininerosedramaticallyinvehicle-treatedratsbyday
3( n = 4), and continued to climb by day ﬁve, indicative
of the severity of disease and irreversibility of the injury
(Figures 2(a) and 2(b)). However, when the animals were
treated with BMSC-CM as described above (n = 3), neither
BUNnorcreatininerosedramaticallyatanypointduringthe
ﬁrst ﬁve days after cisplatin administration. This indicated
that BMSC-CM prevented extensive injury of the kidneys
and preserved enough of the architecture and function of the
kidneys such that clearance of BUN and creatinine was not
greatly aﬀected.
3.2. BMSC-CM Partially Preserves Histological Integrity of the
Kidney in Rats Treated with Cisplatin. From the results of
the renal function markers, BUN and creatinine, it seemed
likely that the BMSC-CM treatment was protecting the
architecture of the kidney, thereby preserving GFR. When
the rats were subjected to a lethal dose of cisplatin and
then treated with saline (n = 4), H&E staining of the
kidneys revealed cortical damage in the form of collapsed
Bowman’s capsule and proximal tubular necrosis, and outer
medullary damage in the form of extensive tubular necrosis,
deposition of debris and tubule casts, all consistent with
cisplatin-mediated AKI (Figure 3). The injury was so severe
that upon excision, the kidneys were grossly hemorrhagic
and the normal tissue ﬁrmness was replaced with softness.
The kidneys of the rats administered BMSC-CM (n = 3),
on the other hand, sustained signiﬁcantly less injury. H&E
analysis revealed less tubular necrosis, diminished loss of4 Stem Cells International
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Figure 1: BMSC-CM confers a signiﬁcant survival beneﬁt to
rats undergoing lethal cisplatin-induced AKI. At hour 0, cisplatin
dissolvedinphysiologicalsaline(0.75mg/mL)wasadministeredi.p.
to male, SAS-SD rats at a lethal dose (7.5mg/kg). At hours 3, 9, 24,
48, and 72, 1mL of either physiological saline (n = 12), ﬁbroblast
conditioned medium (n = 10) or BMSC-conditioned medium
(n = 14) were administered i.v. to the cisplatin-treated AKI rats.
They were monitored for survival for 30 days. ∗P<0.05 for BMSC-
CM compared to both FB-CM and saline by Logrank test.
brush borders, decreased denuding of tubular epithelium,
and a reduction in apparent casts or accumulated debris.
We next sought to analyze apoptosis in the kidneys
during cisplatin toxicity. TUNEL analysis on day-5 kidney
sections revealed extensive apoptotic foci in the medulla of
the vehicle-treated kidneys, consistent with injury patterns
in the pars recta of the proximal tubule that are precipitated
by cisplatin [33]( n = 4, Figure 4(a)). We did not
observe signiﬁcant TUNEL positive staining in the cortex
of these animals. The observed medullary apoptosis in the
vehicle-treated animals was not present in the BMSC-CM
treated animals (n = 3). Periodic apoptotic cells were
observed in the BMSC-CM treated kidneys, but there were
approximately 10X more in the vehicle-treated kidneys,
indicating far fewer apoptotic events in BMSC-CM-treated
kidneys (Figure 4(b)).
We then looked into the prevalence of markers of
regenerationinthekidneystotestthehypothesisthatBMSC-
CM treatment may facilitate regeneration, which could
contribute recovery of the animals. PCNA expression was far
more extensive in the BMSC-CM treated kidneys (n = 3)
than healthy control kidneys (n = 3) that only showed scarce
PCNA-positive cells (less than one per 10X ﬁeld on average,
data not shown) (Figure 5)[ 34]. We quantiﬁed the number
of PCNA positive cells in each 20X ﬁeld, and found that
the extent of positive staining in vehicle-treated kidneys was
signiﬁcantly higher than in BMSC-CM treated kidneys.
3.3. IL-10 Is Important for BMSC-CM Therapy in AKI. Since
we saw such a strong response in the rats to BMSC-CM
in AKI, we explored mechanistic implications of BMSC-
CM therapy, in particular how BMSC-CM might inﬂuence
the immune state of the animal during AKI. Our previous
work revealed that during liver failure, the inﬂammatory
state of rats treated with BMSC-CM was reduced compared
t ov e h i c l ec o n t r o l s[ 24]: the vehicle-treated rats developed
high systemic levels of IL-1β,T N F - α, IL-6, and IL-1ra, and
low levels of IL-10, while BMSC-CM treated rats developed
high levels of IL-10 and lower levels of IL-1β,T N F - α,I L - 6
and IL-1ra. In other models as well, IL-10 upregulation has
been shown to be a hallmark of BMSC therapy [13, 35], and
has been shown to inﬂuence the expression of IL-1β,T N F - α,
and IL-6 in vitro and in vivo [16, 36]. We evaluated whether
BMSC-CMtreatmentresultedinenhancedIL-10expression.
The serum level of IL-10 in BMSC-CM treated rats (n = 3)
three days after cisplatin administration was signiﬁcantly
higher than that in vehicle controls (n = 4, Figure 6(a)).
To conﬁrm that the IL-10 we measured did not arise from
the BMSC-CM that we injected, we determined the amount
of IL-10 in BMSC-CM. Even though the BMSC-CM was
from human cells and the IL-10 we measured in the animals
was rat, we nevertheless wanted to conﬁrm there was no
cross-reactivity in the ELISA and measured the BMSC-CM
independently. We found that the minute positive reactivity
of BMSC-CM in the ELISA could not account for the IL-10
seen in the serum (Figure 6(b)).
Finally, to test the extent to which IL-10 may be
responsible for the therapeutic eﬀectiveness of the BMSC-
CM treatment in AKI, we used the same survival model of
cisplatin AKI (7.5mg/kg) and coadministered BMSC-CM
with neutralizing IL-10 antibody at 4μg per dose. Figure 7
shows the diminished eﬀect of BMSC-CM on the survival
of animals when coadministered with neutralizing IL-10
antibody (n = 10) compared to the survival data presented
in Figure 1: fewer animals survived when IL-10 antibody
was coadministered with BMSC-CM. It should be noted that
when tested for signiﬁcance using the log rank test, the P
value of the diﬀerences between BMSC-CM versus BMSC-
CM with IL-10 antibody were 0.28, suggesting trends rather
than signiﬁcant increases or decreases in survival. Therefore,
tofurthercharacterizetheeﬀectofIL-10antibodyonBMSC-
CM administration, H&E histology was performed for the
three treatment groups: saline (n = 3), BMSC-CM, (n =
3), or BMSC-CM with 4μgo fI L - 1 0a n t i b o d y( n = 3).
Staining for the kidney injury marker, KIM-1 and serum
analysis of kidney injury markers BUN and creatinine were
also performed on the same groups. BUN and creatinine
were chosen as common markers of kidney injury, and KIM-
1 was chosen as a more speciﬁc and sensitive marker of
directkidneyinjury[27,37,38].H&Ehighlighteddiﬀerences
between the severity of tissue injury as a result of IL-10
neutralization (Figure 8(a)) and histological scoring revealed
a distinction between the kidneys treated with BMSC-CMStem Cells International 5
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Figure 2: BMSC-CM prevents onset of severe AKI. Blood was collected from rats subjected to lethal cisplatin (7.5mg/kg) i.p. via tail snip
1, 3, and 5 days following cisplatin administration. The rats were treated at 3, 9, 24, 48, and 72 hours following cisplatin administration,
with 1mL of either physiological saline (n = 4), or BMSC-conditioned medium (n = 3) i.v. (a) BUN and (b) creatinine were measured to
monitor the extent of renal injury as a function of time after cisplatin. ∗P<0.01 by Student’s t-test.
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Figure 3: BMSC-CM protects the native architecture of the kidney during AKI. Hematoxylin and eosin staining of sections of kidneys from
rats administered a lethal dose of cisplatin (7.5mg/kg) and sacriﬁced at 5 days following cisplatin administration. The rats were treated at 3,
9, 24, 48, and 72 hours following cisplatin administration, with 1mL of either physiological saline (n = 4), or BMSC-conditioned medium
(n = 3) i.v. Scale bar = 200μm.6 Stem Cells International
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Figure 4: BMSC-CM prevents apoptosis in the outer medulla. (a) TUNEL staining was performed on sections of formalin ﬁxed and paraﬃn-
embedded kidneys from rats administered a lethal dose of cisplatin (7.5mg/kg) and sacriﬁced at 5 days following cisplatin administration.
The arrows indicate TUNEL positive cells. The rats were treated at 3, 9, 24, 48 and 72 hours following cisplatin administration, with 1mL
of either physiological saline (n = 4), or BMSC conditioned medium (n = 3) i.v. (b) Quantiﬁcation of the TUNEL positive cells per ﬁeld of
view. Scale bar = 200μm. ∗P<0.01 by Student’s T-test.
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Figure 5: Vehicle treated have a greater number of PCNA+ cells 5 days after cisplatin administration. (a) PCNA staining was performed on
sections of formalin ﬁxed and paraﬃn-embedded kidneys from rats administered a lethal dose of cisplatin (7.5mg/kg) and sacriﬁced at 5
days following cisplatin administration. The rats were treated at 3, 9, 24, 48 and 72 hours following cisplatin administration, with 1mL of
either physiological saline (n = 4), or BMSC conditioned medium (n = 3) i.v. (b) Quantiﬁcation of the PCNA positive cells per ﬁeld of view.
Scale bar = 200μm.Stem Cells International 7
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Figure 6: BMSC-CM signiﬁcantly upregulates IL-10 in AKI rats, and BMSC-CM is not an exogenous source of IL-10. (a) Rat serum IL-10
was measured via ELISA from rats administered a lethal dose of cisplatin (7.5mg/kg) and then treated with either vehicle or BMSC-CM at
3, 9, 24, 48, and 72 hours after cisplatin administration. Blood was collected via tail snip, and the serum was analyzed on day 3. ∗P<0.05 by
Student’s t-test. (b) IL-10 was measured via ELISA in whole BMSC-CM.
and those with IL-10 neutralizing antibody (Figure 8(b)). In
all groups, the injury to the outer medulla was too severe to
see a diﬀerence between the treatment arms; however, in the
inner and outer cortex, BMSC-CM treated animals exhibited
signiﬁcantly less injury than vehicle-treated and BMSC-
CM plus neutralizing IL-10 antibody treated. Supportive of
the survival results, the injury evident from H&E staining
among the antibody treated animals was as severe as those
treated with vehicle. As these results are partially subjective,
future studies that quantify the injury more completely
might further elucidate the eﬀect of IL-10 neutralization
on tissue injury. Nevertheless, these same results were
reﬂected in BUN and creatinine levels (Figure 9)a n dK I M -
1 staining (Figure 10). BMSC-CM treated animals exhibited
signiﬁcantly less BUN and creatinine accumulation and
minimal KIM-1-positive staining compared to the marked
rise of BUN and creatinine and extensive positive KIM-1
staining of the kidney in vehicle treated and BMSC-CM plus
IL-10antibodiestreatedgroups.Clearlytheseresultssupport
thehypothesisthatIL-10isanimportantmediatorofBMSC-
CM therapy and suggest that through IL-10 upregulation,
BMSC-CM protects the kidney from injury during AKI.
4. Discussion
We have shown that BMSC-CM alone can provide sub-
stantial support in AKI. Several studies have shown that
transplanted BMSCs can provide survival beneﬁt in AKI
akin to what we observed. In one study, i.v. administration
of human BMSCs (2 × 107 cells/kg) in NOD/SCID mice at
24 hours following lethal cisplatin administration enhanced
survivalfrom0%to40%[39].Inanother,i.p.administration
(2 × 108 cells/kg) was demonstrated to be suﬃcient for
providing survival beneﬁt to NOD/SCID mice, enhancing
survival from 10% to 47% [40]. In our study, we used
the secreted factors from the equivalent of 3 × 107 cells/kg,
which is within the same order-of-magnitude as other work
demonstrating i.v. administration of BMSCs, which is why
wemightexpectasimilarresultintermsofprotectionduring
AKI. Nevertheless, this is potentially not a direct comparison
as the BMSC-CM consists of secreted factors from only 24
hours of conditioning, compared to permanent engraftment
of transplanted BMSCs and continuous secretion of factors
over time from the engrafted cells [41]. It should be
recognized, however, that in most cases studied, cell survival
is very transient.
Our results are consistent with other studies of BMSC-
CM in AKI and show for the ﬁrst time that human
BMSC-CM can provide a survival beneﬁt in the context
of AKI. Bi and colleagues showed that in addition to
BMSC transplantation conferring a survival beneﬁt to mice
undergoing cisplatin AKI, mouse BMSC-CM also provided
a 60% increase in survival [42]. We observed a marked
improvement in survival, which we hypothesize could be
attributed to species diﬀerences of the CM [11]. However,
since the study of Bi et al. was executed diﬀerently than ours
with a diﬀerent rodent species, mode of administration of
BMSC-CM, treatment regimen, and BMSC-CM harvesting
method, it is diﬃcult to compare the results of the studies8 Stem Cells International
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Figure 7: IL-10 antibody abates the survival beneﬁt of BMSC-
CM-administered to rats undergoing lethal cisplatin AKI. At hour
0, cisplatin dissolved in physiological saline (0.75mg/mL) was
administered i.p. to male, SAS-SD rats at a lethal dose (7.5mg/kg).
Athours3,9,24,48,and72,1mLofeitherphysiologicalsaline(n =
12), BMSC-conditioned medium (n = 14) or BMSC-conditioned
medium containing 4μg/mL neutralizing anti-rat IL-10 antibody
(n = 10) were administered i.v. to the cisplatin AKI rats. They
were monitored for survival for 30 days. ∗P<0.05 for BMSC-CM
compared to saline by Logrank test.
directly.Also,signiﬁcantprotectionagainstkidneyinjuryhas
been reported from administration of the ultracentrifuged
fraction of BMSC-CM in mice undergoing rhabdomyolytic
AKI [18]. The authors present evidence that microvesicles in
the ultracentrifuged fraction provide beneﬁt by horizontal
gene transfer that is diminished with the coadministra-
tion of RNAse. Protection was, evidenced by histology,
BUN/creatinine, and electron microscopy. Nevertheless, the
authorsdidnotexplorewhethertheultracentrifugedfraction
provides a survival beneﬁt, nor did they report whether the
wholeconditionedmediumcanprovideasimilarorsuperior
beneﬁt. In all, our results here have demonstrated the largest
improvement of survival thus far of any BMSC study to
our knowledge, and show that the secreted factors alone are
suﬃcient for AKI resolution.
Our previous work has shown that the secreted factors
from BMSCs, either administered in the form of condi-
tioned medium (CM) or delivered continuously from an
extracorporeal bioreactor, are capable of providing survival
beneﬁt to animals undergoing fulminant hepatic failure [22,
24]. We observed reversal of the proinﬂammatory cytokine
proﬁle in these animals, with a marked increase in the anti-
inﬂammatory cytokine IL-10. IL-10 has been implicated
in BMSC therapy previously in sepsis [13] and has been
cited as one of the more inﬂuential factors upregulated
during BMSC-mediated T-cell suppression [9, 43]. In sepsis,
BMSCs were shown to upregulate IL-10 in macrophages via
prostaglandin E2-mediated reprogramming. Others groups
have shown that certain factors secreted by BMSCs can
directly lead to IL-10 production [12], including TGF-β [44]
and IL-6 [45], two proteins that are highly expressed by
BMSCs [46, 47]. Clearly there are mechanistic diﬀerences
that distinguish liver failure and sepsis from AKI, and
it was not obvious that the same pattern of cytokine
expression would be seen in AKI rats treated with BMSC-
CM. Nevertheless, IL-10 has also been shown to be eﬀective
as a therapeutic when exogenously delivered to rodents
undergoing AKI [48], conﬁrming the important role that IL-
10 can play in mitigating the disease. It comes as no surprise,
therefore, that we observed upregulation of IL-10, and found
that blocking the cytokine caused a decrease in the survival
of animals treated with BMSC-CM.
In an eﬀo r tt ol e v e r a g ew h a tw eh a v el e a r n e da b o u t
BMSC-CM and begin to translate it to clinical use, we
have recently been working to scale up the extracorporeal
bioreactor we developed to treat fulminant hepatic failure
in rodents [22] to accommodate human use during dialysis
for AKI [49]. In our studies of hepatic failure, we discovered
that continuous delivery of MSC-secreted factors from
a bioreactor can provide a superior therapeutic beneﬁt
compared to bolus administration of BMSC-CM [22]. This
platform might also be applied to existing dialysis circuits to
allow for delivery of BMSC-secreted factors directly into the
bloodstream of patients with AKI undergoing dialysis. When
seeded in the bioreactor, we showed the BMSCs are capable
of remaining viable and functional while retaining their
undiﬀerentiated phenotype under ﬂow conditions mimetic
of clinical operation [49], which suggests that scale-up of
the prototype device from our liver failure studies will likely
result in a similarly active device for clinical use. The results
we report here further support the hypothesis that the
secreted factors from BMSCs delivered into the bloodstream
of animals suﬀering from AKI can fundamentally change the
outcome of those with AKI.
Future work will be required to fully elucidate the
mechanistic details of the phenomena reported here and will
be necessary for rigorous comparison with whole cell trans-
plantation. Our experiments have focused on conditioned
medium obtained by concentrating BMSC supernatants
with a 3kDa cutoﬀ ﬁlter. Small molecule mediators such
as prostaglandin-E2 that are likely important for BMSC
therapeutic activity were physically excluded in these studies
[13, 50]. These and other mediators secreted by BMSCs
are likely important for attenuating inﬂammation as well
as providing mitogenic and angiogenic support to restore
kidney function, and future eﬀorts to uncover their eﬀects
will be informative. We also chose to use human BMSCs to
retain relevance to trials with human BMSCs. However, to
avoid potential xenogenicity, it may also be informative to
repeat these studies with CM from rat BMSCs.
In conclusion, we have demonstrated that BMSC-
secreted factors, independent of cell transplantation, areStem Cells International 9
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capable of stimulating endogenous anti-inﬂammatory pro-
grams via IL-10, leading to a signiﬁcant survival beneﬁt
to rats undergoing cisplatin-induced AKI. These results
suggest that the primary mechanism of BMSC therapy is
based on the secreted factors of the cells, which should
aid in the optimization of proper therapeutic protocols for
treatment of AKI patients with BMSCs. It also suggests
that alternative approaches to cell transplantation might also
prove successful for administering BMSC therapy, including
administration of the conditioned medium as a direct
injectable, or continuous delivery of these secreted factors
from bioreactors into the bloodstream of AKI patients,
thereby circumventing potential risks associated with trans-
plantation [51, 52]. In all, these results present a promising
and innovative new approach to treating AKI that leverages
the natural strengths of the BMSC secretome.
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